+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Isentress"

HIV Drugs and Injectables Market Report 2024-2034 - Product Thumbnail Image

HIV Drugs and Injectables Market Report 2024-2034

  • Report
  • July 2024
  • 288 Pages
  • Global
From
HIV Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032 - Product Thumbnail Image

HIV Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • July 2024
  • 142 Pages
  • Global
From
Fusion Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024-2032 - Product Thumbnail Image

Fusion Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024-2032

  • Report
  • March 2024
  • 118 Pages
  • Global
From
HIV Drugs Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

HIV Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Isentress - API Insight, 2022 - Product Thumbnail Image

Isentress - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
HIV and AIDS Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Thumbnail Image

HIV and AIDS Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • February 2024
  • 87 Pages
  • Global
From
HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Thumbnail Image

HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • November 2023
  • 35 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Isentress is a brand name for the antiretroviral drug raltegravir, which is used to treat HIV/AIDS. It is a type of integrase inhibitor, which works by blocking the action of the HIV enzyme integrase, preventing the virus from replicating. Isentress is usually prescribed in combination with other antiretroviral drugs, and is available in tablet and oral suspension forms. It is generally well-tolerated, with few side effects. Isentress is marketed by Merck & Co., Inc., and is available in many countries around the world. Other companies that market raltegravir include Mylan Pharmaceuticals, Teva Pharmaceuticals, and ViiV Healthcare. Show Less Read more